Michael Nirula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Nirula has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Ajit Kumar Sharma
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
7 shared publications - Anish Thomas
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
7 shared publications - Brett Schroeder
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
6 shared publications - Christopher W. Schultz
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
6 shared publications - George Chrisafis
Univ. of Michigan
6 shared publications - Mohit Kumar Jolly
Department of Bioengineering Indian Institute of Science Bengaluru India
6 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Trial Schema; Gating strategy; KEY RESOURCES table
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Trial Schema; Gating strategy; KEY RESOURCES table
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Clinical Trial Protocol, IRB amendments and DSMB recommendations
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Clinical Trial Protocol, IRB amendments and DSMB recommendations
- Open Access
Hepatobiliary Progenitor-like Reprogramming in Liver Metastases
Metastatic progression requires cancer cells to adapt to the unique constraints of distant organ microenvironments, yet the mechanisms that drive organ-specific adaptations remain poorly understood. Here, we show that the liver actively rewrites metastatic cancer cell identity, driving tumor cells toward a hepatobiliary progenitor-like state. Through integrated transcriptomic, proteomic, metabolomic, and epigenomic analyses of patient-derived rapid-autopsy samples and experimental models, we identify this state as selectively enriched in liver metastases. It is characterized by co-activation of hepatic and biliary/progenitor regulators HNF4A and SOX9 and is observed across multiple epithelial cancers, indicating a conserved response to the hepatic niche. Mechanistically, hepatocyte-derived TGF-β and hypoxia converge to activate a HIF-1α-ACLY axis, increasing nuclear acetyl-coenzyme A availability and histone acetylation at hepatic lineage regulatory elements to drive hepatobiliary reprogramming. This coordinated niche-response program can be captured transcriptionally and is associated with inferior overall survival. Disruption of this pathway suppresses hepatic reprogramming and impairs liver metastatic fitness. These findings identify the liver as an active determinant of metastatic cell fate, linking microenvironmental signaling to metabolic and chromatin remodeling programs that enable lineage plasticity. More broadly, they reveal organ-specific reprogramming as a fundamental principle of metastasis and a therapeutic vulnerability in liver metastases.
Open AccessHepatobiliary Progenitor-like Reprogramming in Liver Metastases
Metastatic progression requires cancer cells to adapt to the unique constraints of distant organ microenvironments, yet the mechanisms that drive organ-specific adaptations remain poorly understood. Here, we show that the liver actively rewrites metastatic cancer cell identity, driving tumor cells toward a hepatobiliary progenitor-like state. Through integrated transcriptomic, proteomic, metabolomic, and epigenomic analyses of patient-derived rapid-autopsy samples and experimental models, we identify this state as selectively enriched in liver metastases. It is characterized by co-activation of hepatic and biliary/progenitor regulators HNF4A and SOX9 and is observed across multiple epithelial cancers, indicating a conserved response to the hepatic niche. Mechanistically, hepatocyte-derived TGF-β and hypoxia converge to activate a HIF-1α-ACLY axis, increasing nuclear acetyl-coenzyme A availability and histone acetylation at hepatic lineage regulatory elements to drive hepatobiliary reprogramming. This coordinated niche-response program can be captured transcriptionally and is associated with inferior overall survival. Disruption of this pathway suppresses hepatic reprogramming and impairs liver metastatic fitness. These findings identify the liver as an active determinant of metastatic cell fate, linking microenvironmental signaling to metabolic and chromatin remodeling programs that enable lineage plasticity. More broadly, they reveal organ-specific reprogramming as a fundamental principle of metastasis and a therapeutic vulnerability in liver metastases.
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.
- Open Access
Metastatic organotropism in small cell lung cancer
Metastasis is the leading cause of cancer-related deaths, yet its regulatory mechanisms are not fully understood. Small-cell lung cancer (SCLC) is the most metastatic form of lung cancer, with most patients presenting with widespread disease, making it an ideal model for studying metastasis. However, the lack of suitable preclinical models has limited such studies. We utilized rapid autopsy-derived tumors to develop xenograft models that mimic key features of SCLC, including histopathology, rapid and widespread development of metastasis to the liver, brain, adrenal, bone marrow, and kidneys within weeks, and response to chemotherapy. By integrating in vivo lineage selection with comprehensive bulk and single cell multiomic profiling of transcriptomes and chromatin accessibility, we identified critical cellular programs driving metastatic organotropism to the liver and brain, the most common sites of SCLC metastasis. Our findings reveal the key role of nuclear-cytoskeletal interactions in SCLC liver metastasis. Specifically, the loss of the nuclear envelope protein lamin A/C, encoded by the LMNA gene, increased nuclear deformability and significantly increased the incidence of liver metastasis. Human liver metastases exhibited reduced LMNA expression compared to other metastatic sites, correlating with poorer patient outcomes and increased mortality. This study introduces novel preclinical models for SCLC metastasis and highlights pathways critical for organ-specific metastasis, offering new avenues for the development of targeted therapies to prevent or treat metastatic disease.
Open AccessMetastatic organotropism in small cell lung cancer
Metastasis is the leading cause of cancer-related deaths, yet its regulatory mechanisms are not fully understood. Small-cell lung cancer (SCLC) is the most metastatic form of lung cancer, with most patients presenting with widespread disease, making it an ideal model for studying metastasis. However, the lack of suitable preclinical models has limited such studies. We utilized rapid autopsy-derived tumors to develop xenograft models that mimic key features of SCLC, including histopathology, rapid and widespread development of metastasis to the liver, brain, adrenal, bone marrow, and kidneys within weeks, and response to chemotherapy. By integrating in vivo lineage selection with comprehensive bulk and single cell multiomic profiling of transcriptomes and chromatin accessibility, we identified critical cellular programs driving metastatic organotropism to the liver and brain, the most common sites of SCLC metastasis. Our findings reveal the key role of nuclear-cytoskeletal interactions in SCLC liver metastasis. Specifically, the loss of the nuclear envelope protein lamin A/C, encoded by the LMNA gene, increased nuclear deformability and significantly increased the incidence of liver metastasis. Human liver metastases exhibited reduced LMNA expression compared to other metastatic sites, correlating with poorer patient outcomes and increased mortality. This study introduces novel preclinical models for SCLC metastasis and highlights pathways critical for organ-specific metastasis, offering new avenues for the development of targeted therapies to prevent or treat metastatic disease.